These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 4938074)

  • 1. [Administration of a dopamine-hydroxylase inhibitor to Parkinson's disease patients].
    Irigoyen M; Serrano PA
    Prensa Med Mex; 1971; 36(7):291-4. PubMed ID: 4938074
    [No Abstract]   [Full Text] [Related]  

  • 2. Hypotension with anesthesia in disulfiram-treated patients.
    Diaz JH; Hill GE
    Anesthesiology; 1979 Oct; 51(4):366-8. PubMed ID: 90468
    [No Abstract]   [Full Text] [Related]  

  • 3. [Disulfiram (anticol) psychoses].
    Gyuris J; Szalay A
    Orv Hetil; 1986 Oct; 127(40):2435-7. PubMed ID: 3537906
    [No Abstract]   [Full Text] [Related]  

  • 4. Control experiment in man on the sedative effect of disulfiram, an inhibitor of dopamine-beta-hydroxylase.
    Auriol B; Bardou E; Lambic C
    Biol Psychiatry; 1980 Aug; 15(4):623-5. PubMed ID: 7397293
    [No Abstract]   [Full Text] [Related]  

  • 5. 5-hydroxyindole levels in rat brain after inhibition of dopamine -hydroxylase.
    Johnson GA; Kim EG; Boukma SJ
    J Pharmacol Exp Ther; 1972 Mar; 180(3):539-46. PubMed ID: 5012781
    [No Abstract]   [Full Text] [Related]  

  • 6. [Hypotension and ST-segment depression in response to disulfiram-ethanol].
    López-Cuenca S; González-Gómez A; Martín-Pellicer A; Fraile-Sanz A; Pastor A; Palacios F
    Med Intensiva; 2013 Oct; 37(7):495-6. PubMed ID: 23158867
    [No Abstract]   [Full Text] [Related]  

  • 7. [Mechanism of the development of akinesia in Parkinson's disease --with reference to L-threo-DOPS therapy].
    Narabayashi H
    No To Shinkei; 1983 Nov; 35(11):1057-63. PubMed ID: 6362685
    [No Abstract]   [Full Text] [Related]  

  • 8. Rotigotine: Parkinson's disease: a step backward.
    Prescrire Int; 2008 Apr; 17(94):60. PubMed ID: 18516813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Which drug to use for the initiation of treatment for early Parkinson's disease].
    Marttila R
    Duodecim; 2004; 120(5):587-90. PubMed ID: 15060995
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibition of dopamine beta-hydroxylase by aromatic and alkyl thioureas.
    Johnson GA; Boukma SJ; Kim EG
    J Pharmacol Exp Ther; 1969 Aug; 168(2):229-34. PubMed ID: 5803305
    [No Abstract]   [Full Text] [Related]  

  • 12. Reduced Gs protein function and G alpha s levels in leukocytes of patients with Parkinson's disease.
    Avissar S; Barki-Harrington L; Herishanu Y; Schreiber G
    Mov Disord; 1997 Mar; 12(2):167-74. PubMed ID: 9087974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disulfiram: old addiction drug gains new support.
    Stezhka T
    Expert Rev Clin Pharmacol; 2013 Mar; 6(2):101. PubMed ID: 23593718
    [No Abstract]   [Full Text] [Related]  

  • 14. Age bias in clinical trials of Parkinson's disease treatment.
    Rajapakse A; Rajapakse S; Playfer J
    J Am Geriatr Soc; 2008 Dec; 56(12):2353-4. PubMed ID: 19093937
    [No Abstract]   [Full Text] [Related]  

  • 15. mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse.
    Gaval-Cruz M; Weinshenker D
    Mol Interv; 2009 Aug; 9(4):175-87. PubMed ID: 19720750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experimentation with apomorphine in Parkinson's disease.
    Castaigne P; Laplane D; Dordain G
    Res Commun Chem Pathol Pharmacol; 1971 Mar; 2(2):154-8. PubMed ID: 4948431
    [No Abstract]   [Full Text] [Related]  

  • 18. Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease.
    Schapira AH; Olanow CW
    Ann Neurol; 2003; 53 Suppl 3():S149-57; discussion S157-9. PubMed ID: 12666106
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of Parkinson's disease. From theory to practice.
    Ahlskog JE
    Postgrad Med; 1994 Apr; 95(5):52-4, 57-8, 61-4 passim. PubMed ID: 8153048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of fusaric acid, inhibitor of dopamine -hydroxylase, on reaction to alcohol in chronic alcoholics: clinical findings.
    Ogata M; Sanada H; Teraoka M
    Folia Psychiatr Neurol Jpn; 1972 Jan; 26(1):1-5. PubMed ID: 5068469
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.